Magnesium Sulfate Improves Some Risk Factors for Atherosclerosis in Patients Suffering from One or Two Coronary Artery Diseases: A Double-blind Clinical Trial Study

Given the beneficial effect of MgSO on the cardiovascular system, this study was designed to investigate the effect of MgSO administration on suppressing some atherosclerotic risk factors in moderate coronary artery disease patients with one or two atherosclerotic vessels. In a randomized double-bli...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology: advances and applications 2020-01, Vol.12, p.159-169
Main Authors: Sobhani, Ali Reza, Farshidi, Hossein, Azarkish, Fariba, Eslami, Mahdiya, Eftekhar, Ebrahim, Keshavarz, Mansoor, Soltani, Nepton
Format: Article
Language:English
Subjects:
Adrenal glands
Atherosclerosis
Cardiovascular disease
Catecholamines
Cholesterol
Clinical trials
Coronary vessels
crp
Diabetes
Double-blind studies
fibrinogen
Homocysteine
Intervention
Medical imaging
mgso4
Original Research
Plasma
Risk factors
Smooth muscle
thyroid hormones
Uric acid
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Given the beneficial effect of MgSO on the cardiovascular system, this study was designed to investigate the effect of MgSO administration on suppressing some atherosclerotic risk factors in moderate coronary artery disease patients with one or two atherosclerotic vessels. In a randomized double-blind placebo-controlled clinical trial study, 64 patients with moderate coronary artery disease (55-69% stenosis) were selected according to angiography findings. Patients were divided into four groups including patients with one or two atherosclerotic vessels treated with MgSO (Mg-treated-VR1, Mg-treated-VR2, respectively), placebo treated patients with one or two atherosclerotic vessels (Control-VR1, Control-VR2, respectively). The patients received either placebo or MgSO supplement capsule containing 300 mg MgSO for six months on a daily basis. ESR, Ca/Mg ratio, urine Mg level, serum Mg, fibrinogen, homocysteine, uric acid, Na, K, Ca, CRP, T3, T4, TSH, BUN, and Cr concentrations were measured at baseline and every three months. Serum T3, Ca, K, homocysteine, CRP, and Mg concentrations were significantly improved in Mg-treated groups compared to placebo groups. The results of this study showed that despite the slight change in serum magnesium level, oral administration of MgSO for six months could slightly reduce the serum levels of some inflammatory and vascular factors in moderate coronary artery disease patients.
ISSN:1179-1438
1179-1438
DOI:10.2147/CPAA.S261264